Major Neurologic Risks of Tranexamic Acid
The primary neurologic risk of tranexamic acid is seizures, which can range from focal myoclonic jerks to generalized convulsions, particularly when administered at high doses, via incorrect routes (especially intrathecal), or in patients with renal dysfunction. 1
Seizure Risk
Seizures represent the most clinically significant neurologic adverse effect of tranexamic acid. The FDA drug label explicitly warns that TXA may cause both focal and generalized seizures 1. This risk is substantially elevated in specific contexts:
- High-dose administration: Most commonly reported during cardiovascular surgery using doses up to 10-fold higher than recommended 1
- Intrathecal administration: When accidentally given via neuraxial routes instead of intravenously, severe neurotoxicity occurs including myoclonus, generalized seizures, and even cardiac arrhythmias 1, 2, 3
- Renal dysfunction: Accumulation in patients with impaired renal function increases seizure risk 1
Clinical Presentation
Seizure manifestations include:
- Myoclonic movements and twitching 1, 4
- Focal seizures progressing to generalized convulsions 5
- Status epilepticus 6
The FDA recommends EEG monitoring for patients with seizure history or those showing myoclonic movements during TXA administration, and immediate discontinuation if seizures occur 1.
Route-Specific Catastrophic Neurotoxicity
Intrathecal or epidural administration of TXA is absolutely contraindicated and can be fatal. The FDA explicitly states TXA is for intravenous use only, and serious adverse reactions including seizures and cardiac arrhythmias have occurred with inadvertent intrathecal administration 1. Case reports document severe outcomes including:
- Severe back and gluteal pain
- Progressive myoclonus
- Generalized convulsions
- Ventricular tachycardia
- Potential permanent neurologic sequelae 2, 3
Critical safety measure: Syringes must be clearly labeled with the intravenous route to prevent confusion with other injectable solutions 1.
Other Neurologic Effects
Dizziness
TXA may cause dizziness, and the FDA advises patients to avoid driving or operating machinery until they understand how the drug affects them 1. Concomitant use with other medications causing dizziness may worsen this effect 1.
Visual Disturbances
While not observed in humans, animal studies showed retinal degeneration at high doses. The FDA suggests ophthalmic monitoring (visual acuity and optical coherence tomography) for patients treated longer than 3 months 1.
Cerebral Complications (Contraindicated Population)
TXA is absolutely contraindicated in subarachnoid hemorrhage because anecdotal experience indicates it may cause cerebral edema and cerebral infarction in these patients 1.
Context-Specific Safety in Trauma
Importantly, in the trauma setting using standard dosing (1g bolus over 10 minutes followed by 1g over 8 hours), no treatment-related adverse effects were reported in the landmark CRASH-2 trial of over 20,000 patients 7. The 2013 European guidelines similarly note that no adverse events were described with standard TXA dosing in CRASH-2, though they acknowledge increased seizure rates with high-dose TXA in cardiac surgery 8.
The PATCH trial (1,307 patients) also found no difference in thrombotic events between TXA and placebo groups 7.
Risk Mitigation Strategy
To minimize neurologic risks:
- Verify intravenous route - never administer intrathecally or epidurally
- Use standard trauma dosing - 1g over 10 minutes, then 1g over 8 hours 7
- Adjust for renal impairment - reduce dose based on creatinine clearance 1
- Monitor for myoclonus - consider EEG if seizure history or abnormal movements 1
- Discontinue immediately if seizures occur 1
- Avoid in subarachnoid hemorrhage - absolute contraindication 1
The neurologic safety profile at standard trauma doses is reassuring, but vigilance for seizures and absolute avoidance of neuraxial administration are essential.